Home Clinical Impact of the New Criteria for the Diagnosis of Diabetes Mellitus
Article
Licensed
Unlicensed Requires Authentication

Clinical Impact of the New Criteria for the Diagnosis of Diabetes Mellitus

  • Andrew F. B. Kernohan , Colin G. Perry and Michael Small
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 9

Abstract

In 1997 the American Diabetes Association lowered the threshold for diagnosis of diabetes from a fasting plasma glucose concentration of 7.8 mmol/l to 7.0 mmol/l and advised that the oral glucose tolerance test no longer be used in routine clinical practice. In 1999 the World Health Organization endorsed the reduction in fasting plasma glucose threshold but recommended retaining the oral glucose tolerance test for anyone with impaired fasting glucose (6.1 mmol/l–6.9 mmol/l). This Review discusses the impact of these changes on the prevalence of diabetes and examines the implications for individuals and specific high-risk groups. The phenotype of those diagnosed with diabetes and the predictive value for the development of complications according to the different criteria are compared. It is clear that these changes in diagnostic criteria have major importance both for individuals and for resource planning at a national level.

:
Published Online: 2005-06-01
Published in Print: 2003-09-16

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Editors' Introduction: Welcome to the Special Issue on Diabetes Mellitus
  2. Linking Research and Innovative Clinical Practice: The Story of Diabetes Mellitus
  3. Insulin Resistant States and Insulin Signaling
  4. Diabesity: An Inflammatory Metabolic Condition
  5. Plasma Adiponectin and Hyperglycaemia in Diabetic Patients
  6. Platelet Function and Acetyl-Coenzyme A Metabolism in Type 1 Diabetes Mellitus
  7. Oxidative Stress in Diabetes
  8. Carbonyl Stress and Diabetic Complications
  9. Chemical Modification of Proteins by Lipids in Diabetes
  10. Glyoxal and Methylglyoxal Levels in Diabetic Patients: Quantitative Determination by a New GC/MS Method
  11. Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease
  12. Haemoglobin A1c – A Marker for Complications of Type 2 Diabetes: The Experience from the UK Prospective Diabetes Study (UKPDS)
  13. Glycated Hemoglobin Standardization – National Glycohemoglobin Standardization Program (NGSP) Perspective
  14. Haemoglobin A1c: Analysis and Standardisation
  15. Point-of-Care Testing in Diabetes Mellitus
  16. Evaluation of Portable Blood Glucose Meters. Problems and Recommendations
  17. Measurements of Glucose on the Skin Surface, in Stratum Corneum and in Transcutaneous Extracts: Implications for Physiological Sampling
  18. Biological Variability of Albumin Excretion Rate and Albumin-to-Creatinine Ratio in Hypertensive Type 2 Diabetic Patients
  19. Clinical and Laboratory Evaluation of Specific Chemiluminescence Assays for Intact and Total Proinsulin
  20. Clinical Impact of the New Criteria for the Diagnosis of Diabetes Mellitus
  21. The Effect of the New ADA and WHO Guidelines on the Number of Diagnosed Cases of Diabetes Mellitus
  22. Detecting Type 2 Diabetes by a Single Post-Challenge Blood Sample
  23. Laboratory Tests in Diagnosis and Management of Diabetes Mellitus. Practical Considerations
  24. Obesity, Glucose Intolerance and Diabetes and Their Links to Cardiovascular Disease. Implications for Laboratory Medicine
  25. Meetings and Awards
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.190/html
Scroll to top button